Evaluation of the efficacy of upadatinib in the treatment of psoriasis: analysis of treatment duration and effectiveness

Upadacitinib (Upadacitinib) is a new generation of selective JAK1 inhibitor originally developed by AbbVie. It is used for the treatment of a variety of immune-mediated diseases, including rheumatoid arthritis, psoriatic arthritis and moderate to severe plaque psoriasis. Psoriasis is a complex chronic autoimmune skin disease characterized by excessive proliferation of keratinocytes, chronic inflammation, and immune imbalance. Upadatinib by targeting blocking the JAK1 signaling pathway, inhibits the transmission of downstream inflammatory factors (such as IL-23, IL-17, TNF-α, etc.), thereby effectively reducing skin lesions and systemic symptoms.

According to data from multiple international clinical trials (such asSELECT-PsA 1 and SELECT-PsA 2 studies), upadatinib has shown significant effects in the treatment of psoriasis. In terms of treatment course, significant clinical improvement can be observed in the 12th week after treatment, with more than 70% of patients reaching the standard of PASI75 (75% improvement in psoriasis area and severity index) at this time, and some patients can further reach PASI90 or PASI100 (complete clearance). The efficacy continued to increase from 16 to 24 weeks, showing that upadatinib has good durability in mid- to long-term treatment.

In addition, upadatinib not only improves skin symptoms, but also effectively controls joint pain, swelling, morning stiffness and other symptoms in psoriatic arthritis, improving patients' quality of life. During long-term use, the effective rate can still be maintained at over 60%-70%. It is suitable for patients who have poor response to traditional topical drugs, biological agents or other oral small molecule drugs (such as methotrexate and cyclosporine).

Overall, the efficacy evaluation of upadatinib in the treatment of psoriasis has been widely recognized by international medical literature. Due to its characteristics of oral use, fast onset, long-lasting effect, and dual improvement of skin and joints, it is gradually becoming a new choice for the treatment of patients with moderate to severe psoriasis and psoriatic arthritis.

Reference materials:https://www.rinvoq.com/